secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K/A
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001628280-24-026140
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics completes acquisition of AlmataBio; discloses audited financials and pro forma info
--------------------------------------------------------------------------------

- AlmataBio net loss of $659k from inception (April 28, 2023) to Dec 31, 2023; cash $1.8M, total assets $1.8M.
- Acquired anti-IL-1β asset (AVTX-009) from Leap Therapeutics for $500k cash plus potential milestones up to $70M development/regulatory and $720M sales-based.
- Deal closed March 27, 2024, structured as stock-for-stock: AlmataBio equity exchanged for Avalo common and non-voting convertible preferred stock.
- Unaudited pro forma combined statements for year ended Dec 31, 2023 and Q1 2024 filed as Exhibit 99.2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024026140/0001628280-24-026140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024026140/avtx-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-026140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer